| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| Other Sizes |
| Targets |
ε-NAD targets NAD⁺-dependent enzymes, including dehydrogenases, ADP-ribosyltransferases, and sirtuins. As a fluorescent analog of NAD⁺, it can be used as a substrate or cofactor for these enzymes, enabling the study of enzyme activity through fluorescence detection.
|
|---|---|
| ln Vitro |
The in vitro activity of ε-NAD is its function as a fluorescent analog of NAD⁺ for studying NAD⁺-dependent enzymes. The compound exhibits fluorescence with excitation and emission maxima around 305 nm and 410 nm, respectively. It can be used as a substrate or cofactor in enzymatic assays to monitor enzyme activity and protein interactions.
|
| ln Vivo |
ε-NAD is not used as a therapeutic agent. Its in vivo utility is limited to research applications involving the study of NAD⁺-dependent enzymes and metabolic pathways. The compound is not intended for systemic therapeutic use.
|
| Enzyme Assay |
In vitro enzyme assays for ε-NAD involve incubating the fluorescent NAD⁺ analog with NAD⁺-dependent enzymes in appropriate buffer conditions. The enzymatic reaction can be monitored by following changes in the fluorescence properties of ε-NAD or by detecting the fluorescent products of the reaction.
|
| Cell Assay |
For in vitro cellular experiments, ε-NAD can be used to study NAD⁺-dependent enzyme activity in cell lysates or in live cells. The compound can be introduced into cells to monitor metabolic activity and enzyme function.
|
| Animal Protocol |
In vivo animal experiments with ε-NAD are not typically performed, as the compound is primarily used as a research tool for in vitro enzymatic studies. The compound is intended for research use only.
|
| ADME/Pharmacokinetics |
Pharmacokinetic properties of ε-NAD have not been characterized, as the compound is a research-use fluorescent cofactor analog rather than a drug candidate. The compound has a molecular weight of 660.42 g/mol and should be stored under appropriate conditions, protected from light.
|
| Toxicity/Toxicokinetics |
Toxicological data for ε-NAD has not been systematically evaluated, as the compound is intended for research applications only and not for therapeutic use. Standard laboratory safety precautions should be observed.
|
| References | |
| Additional Infomation |
structure
ε-NAD is a fluorescent analog of NAD⁺ used for studying NAD⁺-dependent enzymes, including dehydrogenases, ADP-ribosyltransferases, and sirtuins, in enzymatic assays. The compound has no clinical or therapeutic applications. |
| Molecular Formula |
C23H27N7O14P2
|
|---|---|
| Molecular Weight |
687.45
|
| Exact Mass |
687.109
|
| CAS # |
38806-38-1
|
| PubChem CID |
170119
|
| Appearance |
White to off-white solid powder
|
| LogP |
-4.8
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
17
|
| Rotatable Bond Count |
11
|
| Heavy Atom Count |
46
|
| Complexity |
1200
|
| Defined Atom Stereocenter Count |
8
|
| SMILES |
C1=CC(=C[N+](=C1)[C@H]2[C@@H]([C@@H]([C@H](O2)COP(=O)([O-])OP(=O)(O)OC[C@@H]3[C@H]([C@H]([C@@H](O3)N4C=NC5=C4N=CN6C5=NC=C6)O)O)O)O)C(=O)N
|
| InChi Key |
JCDBQDNBEQHDHK-BSLNIGMPSA-N
|
| InChi Code |
InChI=1S/C23H27N7O14P2/c24-19(35)11-2-1-4-28(6-11)22-17(33)15(31)12(42-22)7-40-45(36,37)44-46(38,39)41-8-13-16(32)18(34)23(43-13)30-10-26-14-20-25-3-5-29(20)9-27-21(14)30/h1-6,9-10,12-13,15-18,22-23,31-34H,7-8H2,(H3-,24,35,36,37,38,39)/t12-,13-,15-,16-,17-,18-,22-,23-/m1/s1
|
| Chemical Name |
[(2R,3S,4R,5R)-5-(3-carbamoylpyridin-1-ium-1-yl)-3,4-dihydroxyoxolan-2-yl]methyl [[(2R,3S,4R,5R)-3,4-dihydroxy-5-imidazo[2,1-f]purin-3-yloxolan-2-yl]methoxy-hydroxyphosphoryl] phosphate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.4547 mL | 7.2733 mL | 14.5465 mL | |
| 5 mM | 0.2909 mL | 1.4547 mL | 2.9093 mL | |
| 10 mM | 0.1455 mL | 0.7273 mL | 1.4547 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
